<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01877655</url>
  </required_header>
  <id_info>
    <org_study_id>0113-CL-1004</org_study_id>
    <secondary_id>2013-000903-18</secondary_id>
    <nct_id>NCT01877655</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)</brief_title>
  <acronym>HELIOS</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as
      measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD)
      through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT
      will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be followed for 5.5 years post-transplant for long-term safety via an
      annual telephone contact.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 11, 2013</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">September 28, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Composite of All-Cause Mortality and Adjudicated Cytomegalovirus End Organ Disease (CMV EOD) Through 1 Year Post Transplant</measure>
    <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
    <description>This was the composite of all-cause mortality and adjudicated CMV EOD through 1 year posttransplant, The CMV EOD was assessed by the independent and blinded adjudication committee, which counted events that were observed up to day 380 from transplantation. Deaths that occurred up to day 365 from transplant were also counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Protocol-Defined CMV Viremia Through 1 Year Posttransplant</measure>
    <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
    <description>Protocol-defined CMV viremia was defined as a CMV plasma viral load ≥1000 IU/mL as assessed by the central laboratory. Rate was based on cumulative incidence function estimated at 1 year. The central laboratory had the lower limit of quantification [LLOQ] for CMV viral load assessment, so when the viral load was below the LLOQ the actual viral load reading was not possible and was denoted as ≤LLOQ. If participant had any CMV viral load assessments greater than the LLOQ it was classified as viremic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adjudicated CMV-Specific Antiviral Therapy (AVT) Through 1 Year Posttransplant</measure>
    <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
    <description>The CMV-specific AVT use was adjudicated by the independent and blinded committee. When the CMV-specific AVT was initiated, a central CMV viral load was obtained weekly until it was discontinued. Participants without any CMV-specific AVT events were censored on the last study evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Composite Endpoint of Protocol-defined CMV Viremia and Adjudicated CMV-Specific AVT Use</measure>
    <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
    <description>Protocol-defined CMV viremia was as CMV plasma viral load ≥ 1000 IU/mL as assessed by the central laboratory. The CMV-specific AVT was determined by the adjudication committee. Participants with no posttransplant viral load data were excluded from the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Occurrence of Adjudicated CMV-specific AVT or Adjudicated Diagnosis of CMV EOD After Study Drug First Injection Through 1 Year Posttransplant</measure>
    <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
    <description>Rate was based on cumulative incidence function estimate at 1 year. Time to first CMV-specific AVT was defined as time to the start of AVT for CMV viremia or CMV EOD. CMV-specific AVT and EOD were determined by the adjudication committee. This endpoint was a composite endpoint based on the independent adjudication committee assessments of CMV-specific AVT and CMV EOD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality at 1 Year Posttransplant</measure>
    <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
    <description>All-cause mortality through 1-year post-transplantation summary included all deaths and unknown survival status. For the known deaths, the adjudication committee assessed results and summarized them according to the following category: Mortality due to the participant's primary disease, and mortality due to causes unrelated to the participant's primary disease. Participants with unknown survival status at 1 year were considered dead for this analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Cytomegalovirus (CMV)-Positive Recipients</condition>
  <condition>Allogeneic, Hematopoietic Cell Transplant (HCT)</condition>
  <arm_group>
    <arm_group_label>ASP0113</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASP0113</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>ASP0113</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is a CMV-seropositive HCT recipient

          -  Participant is planned to undergo either of the following:

               -  Sibling Donor Transplant

               -  Unrelated Donor Transplant

          -  Participant has one of the following underlying diseases:

               -  Acute myeloid leukemia (AML)

               -  Acute lymphoblastic leukemia (ALL)

               -  Acute undifferentiated leukemia (AUL)

               -  Acute biphenotypic leukemia

               -  Chronic myelogenous leukemia (CML)

               -  Chronic lymphocytic leukemia (CLL).

               -  A defined myelodysplastic syndrome(s) (MDS)

               -  Primary or secondary myelofibrosis

               -  Lymphoma (including Hodgkin's)

        Exclusion Criteria:

          -  Participant has active CMV disease or infection or has received treatment for active
             CMV disease or infection within 3 months (90 days) prior to transplant

          -  Participant has a modified hematopoietic cell transplant comorbidity index (HCT-CI)
             score ≥ 4

          -  Participant has received a prior HCT and has residual Chronic Graft-versus-host
             Disease (cGVHD)

          -  Participant who is scheduled to have a cord blood transplant or a haploidentical
             transplant

          -  Participant has a platelet count of less than 50,000 mm3 within 3 days prior to
             randomization (platelet transfusions are allowed)

          -  Participant has aplastic anemia or multiple myeloma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US10028</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10044</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10035</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10026</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10030</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10012</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10013</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10007</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10020</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10010</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10043</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10011</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10021</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10036</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10042</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10023</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601-2105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10047</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10027</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10025</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10016</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10002</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10045</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10046</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10031</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10039</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10024</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10019</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU43001</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>QLD 4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU43004</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32001</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32005</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32007</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15001</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15002</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15004</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15003</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33011</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33005</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33009</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33010</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49010</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49012</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49013</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49014</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49002</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49015</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49007</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49005</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49008</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49006</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49001</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81003</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81011</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81007</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81010</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81008</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81009</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81004</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81001</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81005</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81006</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82004</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82002</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82003</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82001</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34001</name>
      <address>
        <city>Badalona</city>
        <zip>08615</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34006</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34004</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34005</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34003</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34011</name>
      <address>
        <city>Madrid</city>
        <zip>28028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34007</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34010</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34002</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34009</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46001</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46006</name>
      <address>
        <city>Linkoping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46004</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46003</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46005</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88601</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88602</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88603</name>
      <address>
        <city>Taoyuan County</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <results_first_submitted>September 17, 2018</results_first_submitted>
  <results_first_submitted_qc>November 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 28, 2018</results_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP0113</keyword>
  <keyword>Cytomegalovirus (CMV)</keyword>
  <keyword>Hematopoietic Cell Transplant (HCT)</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT01877655/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT01877655/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 514 participants were enrolled across 11 countries. At least 30% of enrolled participants had cytomegalovirus (CMV) seronegative donor and underwent allogeneic hematopoietic cell transplant (HCT). After the primary study period (day 365) participants were monitored for 5.5 years post-transplant for long-term safety.</recruitment_details>
      <pre_assignment_details>Screening assessment occurred from 30 to 5 days before transplant. Participants who met the inclusion and none of the exclusion criteria were randomly assigned in a 1:1 ratio to receive either ASP0113 or placebo. The randomization to treatment was stratified by donor-recipient relatedness and by donor CMV serostatus.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
        </group>
        <group group_id="P2">
          <title>ASP0113 5mg</title>
          <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but Never Received Drug</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population was the All Randomized which consisted of all randomized participants whether they received study drug or not.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
        </group>
        <group group_id="B2">
          <title>ASP0113</title>
          <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="263"/>
            <count group_id="B2" value="251"/>
            <count group_id="B3" value="514"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The analysis population was the all randomized.</population>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="13.15"/>
                    <measurement group_id="B2" value="51.8" spread="12.41"/>
                    <measurement group_id="B3" value="51.9" spread="12.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The analysis population was the all randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>The analysis population was the all randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>The analysis population was the all randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Strata</title>
          <population>The analysis population was the all randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Related Seropositive Donor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Seronegative Donor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-related Seropositive Donor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-related Seronegative Donor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Diagnosis</title>
          <population>The analysis population was the all randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Acute Myeloid Leukemia (AML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Lymphoblastic Leukemia (ALL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Undifferentiated Leukemia (AUL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Biphenotypic Leukemia (ABL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Myelogenous Leukemia (CML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Lymphocytic Leukemia (CLL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary or Secondary Myelofibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conditioning Regimen</title>
          <population>The analysis population was the all randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Myeloablative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Myeloablative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antithymocyte Globulin (ATG) Use</title>
          <population>The analysis population was the all randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>The analysis population was the all randomized.</population>
          <units>Centimeteres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.6" spread="9.91"/>
                    <measurement group_id="B2" value="169.7" spread="9.88"/>
                    <measurement group_id="B3" value="170.2" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>The analysis population was the all randomized.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="5.02"/>
                    <measurement group_id="B2" value="26.0" spread="5.05"/>
                    <measurement group_id="B3" value="26.5" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Composite of All-Cause Mortality and Adjudicated Cytomegalovirus End Organ Disease (CMV EOD) Through 1 Year Post Transplant</title>
        <description>This was the composite of all-cause mortality and adjudicated CMV EOD through 1 year posttransplant, The CMV EOD was assessed by the independent and blinded adjudication committee, which counted events that were observed up to day 380 from transplantation. Deaths that occurred up to day 365 from transplant were also counted.</description>
        <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
        <population>The analysis population was the full analysis set (FAS), which consisted of all randomized participants who received at least one dose of randomized study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>ASP0113</title>
            <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite of All-Cause Mortality and Adjudicated Cytomegalovirus End Organ Disease (CMV EOD) Through 1 Year Post Transplant</title>
          <description>This was the composite of all-cause mortality and adjudicated CMV EOD through 1 year posttransplant, The CMV EOD was assessed by the independent and blinded adjudication committee, which counted events that were observed up to day 380 from transplantation. Deaths that occurred up to day 365 from transplant were also counted.</description>
          <population>The analysis population was the full analysis set (FAS), which consisted of all randomized participants who received at least one dose of randomized study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants With Composite Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.20"/>
                    <measurement group_id="O2" value="35.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-Cause Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.24"/>
                    <measurement group_id="O2" value="31.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjudicated CMV EOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53"/>
                    <measurement group_id="O2" value="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of all-cause mortality and adjudicated CMV EOD. Analysis was completed using the Cochran-Mantel-Haenszel (CMH) test at the 1-sided 5% level stratified by use of antithymocyte globulin (ATG) and by receipt of a kidney from a living or deceased donor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.205</p_value>
            <p_value_desc>P-value based on CMH general association test stratified by donor-recipient relatedness and donor CMV serostatus.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
            <estimate_desc>Odds ratio (ASP0113 vs placebo) and 95% CI was based on CMH general association test stratified by donor-recipient relatedness &amp; donor CMV serostatus.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Protocol-Defined CMV Viremia Through 1 Year Posttransplant</title>
        <description>Protocol-defined CMV viremia was defined as a CMV plasma viral load ≥1000 IU/mL as assessed by the central laboratory. Rate was based on cumulative incidence function estimated at 1 year. The central laboratory had the lower limit of quantification [LLOQ] for CMV viral load assessment, so when the viral load was below the LLOQ the actual viral load reading was not possible and was denoted as ≤LLOQ. If participant had any CMV viral load assessments greater than the LLOQ it was classified as viremic.</description>
        <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>ASP0113</title>
            <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Protocol-Defined CMV Viremia Through 1 Year Posttransplant</title>
          <description>Protocol-defined CMV viremia was defined as a CMV plasma viral load ≥1000 IU/mL as assessed by the central laboratory. Rate was based on cumulative incidence function estimated at 1 year. The central laboratory had the lower limit of quantification [LLOQ] for CMV viral load assessment, so when the viral load was below the LLOQ the actual viral load reading was not possible and was denoted as ≤LLOQ. If participant had any CMV viral load assessments greater than the LLOQ it was classified as viremic.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="52.0" upper_limit="64.6"/>
                    <measurement group_id="O2" value="56.7" lower_limit="50.1" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of CMV viremia through 1 year posttransplant. CMV viremia was defined by the protocol as CMV plasma viral load ≥ 1000 IU/mL as assessed by the central laboratory. The 95% CI was based on cumulative incidence function CMV viremia rate at 1 year.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.748</p_value>
            <p_value_desc>P-value based on cox proportional hazards model parameter estimate for the treatment effect.</p_value_desc>
            <method>Cox Proportional Hazard Model</method>
            <method_desc>Parameter estimate from cox proportional hazard model (ASP0113 v placebo) with treatment &amp; randomization strata adjusted for death as a competing risk</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adjudicated CMV-Specific Antiviral Therapy (AVT) Through 1 Year Posttransplant</title>
        <description>The CMV-specific AVT use was adjudicated by the independent and blinded committee. When the CMV-specific AVT was initiated, a central CMV viral load was obtained weekly until it was discontinued. Participants without any CMV-specific AVT events were censored on the last study evaluation.</description>
        <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>ASP0113</title>
            <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adjudicated CMV-Specific Antiviral Therapy (AVT) Through 1 Year Posttransplant</title>
          <description>The CMV-specific AVT use was adjudicated by the independent and blinded committee. When the CMV-specific AVT was initiated, a central CMV viral load was obtained weekly until it was discontinued. Participants without any CMV-specific AVT events were censored on the last study evaluation.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" lower_limit="46.8" upper_limit="59.1"/>
                    <measurement group_id="O2" value="54.6" lower_limit="48.1" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of CMV-specific antiviral therapy (AVT) through 1 year. Time to first adjudicated CMV-specific therapy was defined as time to the start of AVT for CMV viremia. CMV-specific AVT was determined by the adjudication committee. Rate was based on cumulative incidence function estimate at 1 year.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.888</p_value>
            <p_value_desc>P-value based on cox proportional hazards model parameter estimate for the treatment effect.</p_value_desc>
            <method>Cox Proportional Hazard Model</method>
            <method_desc>Parameter estimate from cox proportional hazard model (ASP0113 v placebo) with treatment &amp; randomization strata adjusted for death as a competing risk</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Composite Endpoint of Protocol-defined CMV Viremia and Adjudicated CMV-Specific AVT Use</title>
        <description>Protocol-defined CMV viremia was as CMV plasma viral load ≥ 1000 IU/mL as assessed by the central laboratory. The CMV-specific AVT was determined by the adjudication committee. Participants with no posttransplant viral load data were excluded from the analysis.</description>
        <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>ASP0113</title>
            <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Composite Endpoint of Protocol-defined CMV Viremia and Adjudicated CMV-Specific AVT Use</title>
          <description>Protocol-defined CMV viremia was as CMV plasma viral load ≥ 1000 IU/mL as assessed by the central laboratory. The CMV-specific AVT was determined by the adjudication committee. Participants with no posttransplant viral load data were excluded from the analysis.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.78"/>
                    <measurement group_id="O2" value="60.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of composite of CMV viremia and adjudicated CMV-AVT. The CMV viremia was defined by the protocol as CMV plasma viral load ≥ 1000 IU/mL as assessed by the central laboratory. CMV-specific AVT was determined by the adjudication committee. Participants with no posttransplant viral load data were excluded from the analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.802</p_value>
            <p_value_desc>P value based on CMH general association test stratified by donor-recipient relatedness and donor CMV serostatus.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>Odds ratio (ASP0113 vs placebo) and 95% CI based on CMH general association test stratified by donor recipient relatedness and donor CMV serostatus.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Occurrence of Adjudicated CMV-specific AVT or Adjudicated Diagnosis of CMV EOD After Study Drug First Injection Through 1 Year Posttransplant</title>
        <description>Rate was based on cumulative incidence function estimate at 1 year. Time to first CMV-specific AVT was defined as time to the start of AVT for CMV viremia or CMV EOD. CMV-specific AVT and EOD were determined by the adjudication committee. This endpoint was a composite endpoint based on the independent adjudication committee assessments of CMV-specific AVT and CMV EOD.</description>
        <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>ASP0113</title>
            <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Occurrence of Adjudicated CMV-specific AVT or Adjudicated Diagnosis of CMV EOD After Study Drug First Injection Through 1 Year Posttransplant</title>
          <description>Rate was based on cumulative incidence function estimate at 1 year. Time to first CMV-specific AVT was defined as time to the start of AVT for CMV viremia or CMV EOD. CMV-specific AVT and EOD were determined by the adjudication committee. This endpoint was a composite endpoint based on the independent adjudication committee assessments of CMV-specific AVT and CMV EOD.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" lower_limit="48.0" upper_limit="60.3"/>
                    <measurement group_id="O2" value="55.4" lower_limit="48.9" upper_limit="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of rate of adjudicated CMV AVT or CMV EOD. Time to first CMV-specific AVT was defined as time to the start of AVT for CMV viremia or CMV EOD. CMV-specific AVT and EOD and were determined by the adjudication committee. Rate based on cumulative incidence function estimate at 1 year.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.928</p_value>
            <p_value_desc>P value based on cox proportional hazards model parameter estimate for the treatment effect.</p_value_desc>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Parameter estimate from cox proportional hazard model (ASP0113 v placebo) with treatment &amp; randomization strata adjusted for death as a competing risk</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Mortality at 1 Year Posttransplant</title>
        <description>All-cause mortality through 1-year post-transplantation summary included all deaths and unknown survival status. For the known deaths, the adjudication committee assessed results and summarized them according to the following category: Mortality due to the participant's primary disease, and mortality due to causes unrelated to the participant's primary disease. Participants with unknown survival status at 1 year were considered dead for this analysis.</description>
        <time_frame>From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>ASP0113</title>
            <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Mortality at 1 Year Posttransplant</title>
          <description>All-cause mortality through 1-year post-transplantation summary included all deaths and unknown survival status. For the known deaths, the adjudication committee assessed results and summarized them according to the following category: Mortality due to the participant's primary disease, and mortality due to causes unrelated to the participant's primary disease. Participants with unknown survival status at 1 year were considered dead for this analysis.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.24"/>
                    <measurement group_id="O2" value="31.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of all-cause mortality at 1 year. Participants with unknown survival status at 1 year were considered dead for this analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.393</p_value>
            <p_value_desc>P value based on cox proportional hazards model parameter estimate for the treatment effect.</p_value_desc>
            <method>Cox Proportional Hazards Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>Odds ratio (ASP0113 vs placebo) and 95% CI based on CMH general association test stratified by donor-recipient relatedness and donor CMV serostatus.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to 30 days after last dose of study drug (Day 365)</time_frame>
      <desc>Treatment Emergent Adverse Event (TEAE) was defined as an adverse event observed after the first dose of study drug injection through Day 365 and within 30 days of the last dose of study drug. Drug-related TEAE was defined as any TEAE with at least possible relationship to study treatment as assessed by the investigator or with missing assessment of the causal relationship.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
        </group>
        <group group_id="E2">
          <title>ASP0113 5mg</title>
          <description>Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Aural polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastrooesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Drug resistance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oedema due to cardiac disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Serositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hepatic vein occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Venoocclusive liver disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease in intestine</sub_title>
                <counts group_id="E1" events="120" subjects_affected="76" subjects_at_risk="255"/>
                <counts group_id="E2" events="123" subjects_affected="76" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease in liver</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="255"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease in skin</sub_title>
                <counts group_id="E1" events="171" subjects_affected="122" subjects_at_risk="255"/>
                <counts group_id="E2" events="165" subjects_affected="118" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Alloimmunisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in intestine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in liver</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Anorectal cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cerebral aspergillosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Citrobacter sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Encephalitis cytomegalovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Encephalitis herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Epstein-Barr viraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hepatic candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Human herpesvirus 6 infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Human polyomavirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia adenoviral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia herpes viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="255"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Systemic mycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Viral haemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Blood stem cell transplant failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Drug dose omission</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Transfusion microchimerism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Computerised tomogram thorax abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Immunosuppressant drug level increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Adult T-cell lymphoma/leukaemia recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chloroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic myelomonocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Leukaemia recurrent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Leukaemic infiltration brain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Monoclonal gammopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma recurrent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Peripheral T-cell lymphoma unspecified recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>T-cell type acute leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="46" subjects_affected="41" subjects_at_risk="255"/>
                <counts group_id="E2" events="38" subjects_affected="28" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Idiopathic pneumonia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Mediastinal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Central venous catheter removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Colectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Donor leukocyte infusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Drug therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Stem cell transplant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Venoocclusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="254" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="244" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="160" subjects_affected="75" subjects_at_risk="255"/>
                <counts group_id="E2" events="146" subjects_affected="66" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="98" subjects_affected="92" subjects_at_risk="255"/>
                <counts group_id="E2" events="101" subjects_affected="91" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="51" subjects_affected="20" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="98" subjects_affected="65" subjects_at_risk="255"/>
                <counts group_id="E2" events="99" subjects_affected="65" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="111" subjects_affected="48" subjects_at_risk="255"/>
                <counts group_id="E2" events="131" subjects_affected="49" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="39" subjects_affected="37" subjects_at_risk="255"/>
                <counts group_id="E2" events="45" subjects_affected="42" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="83" subjects_affected="60" subjects_at_risk="255"/>
                <counts group_id="E2" events="84" subjects_affected="62" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="255"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="128" subjects_affected="103" subjects_at_risk="255"/>
                <counts group_id="E2" events="119" subjects_affected="90" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="244" subjects_affected="167" subjects_at_risk="255"/>
                <counts group_id="E2" events="242" subjects_affected="166" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="255"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="255"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="255"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="261" subjects_affected="177" subjects_at_risk="255"/>
                <counts group_id="E2" events="273" subjects_affected="178" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="255"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="96" subjects_affected="69" subjects_at_risk="255"/>
                <counts group_id="E2" events="105" subjects_affected="79" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="178" subjects_affected="122" subjects_at_risk="255"/>
                <counts group_id="E2" events="195" subjects_affected="125" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="34" subjects_at_risk="255"/>
                <counts group_id="E2" events="39" subjects_affected="30" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="59" subjects_affected="44" subjects_at_risk="255"/>
                <counts group_id="E2" events="46" subjects_affected="36" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="80" subjects_affected="69" subjects_at_risk="255"/>
                <counts group_id="E2" events="65" subjects_affected="58" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" events="72" subjects_affected="49" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="57" subjects_affected="38" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="83" subjects_affected="47" subjects_at_risk="255"/>
                <counts group_id="E2" events="1053" subjects_affected="193" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="36" subjects_affected="24" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="147" subjects_affected="101" subjects_at_risk="255"/>
                <counts group_id="E2" events="94" subjects_affected="75" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E2" events="39" subjects_affected="35" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="95" subjects_affected="69" subjects_at_risk="255"/>
                <counts group_id="E2" events="88" subjects_affected="66" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="255"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="195" subjects_affected="128" subjects_at_risk="255"/>
                <counts group_id="E2" events="180" subjects_affected="123" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic graft versus host disease</sub_title>
                <counts group_id="E1" events="109" subjects_affected="60" subjects_at_risk="255"/>
                <counts group_id="E2" events="110" subjects_affected="62" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in intestine</sub_title>
                <counts group_id="E1" events="28" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in liver</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="255"/>
                <counts group_id="E2" events="43" subjects_affected="30" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in skin</sub_title>
                <counts group_id="E1" events="51" subjects_affected="46" subjects_at_risk="255"/>
                <counts group_id="E2" events="40" subjects_affected="37" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Engraftment syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypogammaglobulinaemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="255"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="64" subjects_affected="51" subjects_at_risk="255"/>
                <counts group_id="E2" events="68" subjects_affected="45" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" events="141" subjects_affected="96" subjects_at_risk="255"/>
                <counts group_id="E2" events="132" subjects_affected="87" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="255"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="36" subjects_affected="27" subjects_at_risk="255"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="47" subjects_affected="31" subjects_at_risk="255"/>
                <counts group_id="E2" events="66" subjects_affected="33" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="45" subjects_affected="30" subjects_at_risk="255"/>
                <counts group_id="E2" events="49" subjects_affected="30" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="43" subjects_affected="21" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="42" subjects_affected="29" subjects_at_risk="255"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" events="26" subjects_affected="15" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="70" subjects_affected="33" subjects_at_risk="255"/>
                <counts group_id="E2" events="62" subjects_affected="28" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="83" subjects_affected="37" subjects_at_risk="255"/>
                <counts group_id="E2" events="49" subjects_affected="28" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="65" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="45" subjects_affected="24" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="109" subjects_affected="91" subjects_at_risk="255"/>
                <counts group_id="E2" events="89" subjects_affected="72" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" events="31" subjects_affected="13" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="90" subjects_affected="66" subjects_at_risk="255"/>
                <counts group_id="E2" events="81" subjects_affected="54" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="43" subjects_affected="30" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="30" subjects_at_risk="255"/>
                <counts group_id="E2" events="53" subjects_affected="24" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="58" subjects_affected="37" subjects_at_risk="255"/>
                <counts group_id="E2" events="51" subjects_affected="28" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="120" subjects_affected="83" subjects_at_risk="255"/>
                <counts group_id="E2" events="140" subjects_affected="92" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="157" subjects_affected="113" subjects_at_risk="255"/>
                <counts group_id="E2" events="168" subjects_affected="113" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="25" subjects_at_risk="255"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="255"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="255"/>
                <counts group_id="E2" events="42" subjects_affected="30" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="255"/>
                <counts group_id="E2" events="52" subjects_affected="44" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="255"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="255"/>
                <counts group_id="E2" events="37" subjects_affected="32" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="38" subjects_affected="33" subjects_at_risk="255"/>
                <counts group_id="E2" events="44" subjects_affected="33" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="153" subjects_affected="103" subjects_at_risk="255"/>
                <counts group_id="E2" events="150" subjects_affected="103" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="49" subjects_affected="46" subjects_at_risk="255"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="53" subjects_affected="44" subjects_at_risk="255"/>
                <counts group_id="E2" events="42" subjects_affected="40" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="85" subjects_affected="76" subjects_at_risk="255"/>
                <counts group_id="E2" events="86" subjects_affected="72" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="255"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="71" subjects_affected="60" subjects_at_risk="255"/>
                <counts group_id="E2" events="71" subjects_affected="55" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="53" subjects_affected="44" subjects_at_risk="255"/>
                <counts group_id="E2" events="50" subjects_affected="40" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="255"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="42" subjects_affected="41" subjects_at_risk="255"/>
                <counts group_id="E2" events="33" subjects_affected="30" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="255"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="255"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="255"/>
                <counts group_id="E2" events="50" subjects_affected="34" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="85" subjects_affected="67" subjects_at_risk="255"/>
                <counts group_id="E2" events="67" subjects_affected="59" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="61" subjects_affected="52" subjects_at_risk="255"/>
                <counts group_id="E2" events="67" subjects_affected="51" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="96" subjects_affected="83" subjects_at_risk="255"/>
                <counts group_id="E2" events="78" subjects_affected="66" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="37" subjects_affected="36" subjects_at_risk="255"/>
                <counts group_id="E2" events="50" subjects_affected="39" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In Oct 2014 data monitoring committee informed Astellas of the results of the first futility analysis. The FDA considered data for 68 participants included in futility analysis compromised and asked that it is not included in final efficacy analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure</name_or_title>
      <organization>Astellas Pharma Global Development, Inc.</organization>
      <phone>800-888-7704</phone>
      <email>astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

